[go: up one dir, main page]

NO20060580L - N-[3-(3-substituerte-pyrazolo[1,5 a]pyrimidin-7-yl)- fenyl]-sulfonamider samt preparater og metoder relatert dertil - Google Patents

N-[3-(3-substituerte-pyrazolo[1,5 a]pyrimidin-7-yl)- fenyl]-sulfonamider samt preparater og metoder relatert dertil

Info

Publication number
NO20060580L
NO20060580L NO20060580A NO20060580A NO20060580L NO 20060580 L NO20060580 L NO 20060580L NO 20060580 A NO20060580 A NO 20060580A NO 20060580 A NO20060580 A NO 20060580A NO 20060580 L NO20060580 L NO 20060580L
Authority
NO
Norway
Prior art keywords
pyrazolo
sulfonamides
pyrimidin
preparations
phenyl
Prior art date
Application number
NO20060580A
Other languages
English (en)
Inventor
Antonio Guglietta
Luis Anglada
Albert Palomer
Marta Princep
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of NO20060580L publication Critical patent/NO20060580L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I: der Ri er som angitt i kravene. Forbindelsene har spesifikk affinitet for GABAa reseptor og er derfor nyttige ved behandling eller hindring av sykdommer modulert av ai- og olx- GABAa reseptorer.
NO20060580A 2003-07-24 2006-02-03 N-[3-(3-substituerte-pyrazolo[1,5 a]pyrimidin-7-yl)- fenyl]-sulfonamider samt preparater og metoder relatert dertil NO20060580L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200301746A ES2222813B1 (es) 2003-07-24 2003-07-24 N-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados.
ES200401697A ES2245894B1 (es) 2003-07-24 2004-07-12 Mejoras en el objeto de la patente de invencion n.p200301746 que se refiere a "n-(3-(3-sustituidas-pirazolo(1,5-a)pirimidin-7-il)-fenil)-sulfonamidas y composiciones y metodos relacionados".
PCT/EP2004/008208 WO2005014597A1 (en) 2003-07-24 2004-07-22 N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO

Publications (1)

Publication Number Publication Date
NO20060580L true NO20060580L (no) 2006-02-03

Family

ID=34137682

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060580A NO20060580L (no) 2003-07-24 2006-02-03 N-[3-(3-substituerte-pyrazolo[1,5 a]pyrimidin-7-yl)- fenyl]-sulfonamider samt preparater og metoder relatert dertil

Country Status (29)

Country Link
US (1) US7947688B2 (no)
EP (1) EP1648897B1 (no)
JP (1) JP2006528608A (no)
KR (1) KR100840450B1 (no)
CN (1) CN100393721C (no)
AR (1) AR047017A1 (no)
AT (1) ATE417048T1 (no)
AU (1) AU2004263278B2 (no)
BR (1) BRPI0412826A (no)
CA (1) CA2532437C (no)
CL (1) CL2004001814A1 (no)
DE (1) DE602004018320D1 (no)
DK (1) DK1648897T3 (no)
EA (1) EA009519B1 (no)
ES (2) ES2222813B1 (no)
HR (1) HRP20060009A2 (no)
IL (1) IL173252A0 (no)
MA (1) MA27944A1 (no)
MX (1) MXPA06000754A (no)
NO (1) NO20060580L (no)
NZ (1) NZ544349A (no)
PA (1) PA8607501A1 (no)
PE (1) PE20050254A1 (no)
PL (1) PL1648897T3 (no)
PT (1) PT1648897E (no)
TW (1) TWI340140B (no)
UA (1) UA81959C2 (no)
UY (1) UY28440A1 (no)
WO (1) WO2005014597A1 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084835A1 (en) * 2005-02-10 2006-08-17 Ferrer Internacional, S. A. N-(3-(imidazo [1,5-a]pyrimidin-4-yl)phenyl]-sulfonamides and n-[3-(imidazo[1,5-a]pyrimidin-4-yl)-phenyl]-carboxamides and their use as gabaa receptor modulators
EP1736475A1 (en) * 2005-06-21 2006-12-27 Ferrer Internacional, S.A. Halogenated pyrazolo[1,5-a]pyrimidines, processes, uses, compositions and intermediates
EP1996594A2 (en) * 2006-03-17 2008-12-03 Wyeth a Corporation of the State of Delaware Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof
EP1845098A1 (en) * 2006-03-29 2007-10-17 Ferrer Internacional, S.A. Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands
EP1884516A1 (en) * 2006-08-04 2008-02-06 Ferrer Internacional, S.A. Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions
EP1956021A1 (en) * 2006-10-11 2008-08-13 Ferrer Internacional, S.A. Process for the manufacture of a crystalline pyrazolo[1,5-a]pyrimidine compound
EP1921079A1 (en) * 2006-11-08 2008-05-14 Ferrer Internacional, S.A. Amorphous form of N-{2-Fluoro-5-[3-(thiophene-2-carbonyl)-pyrazolo[1,5-a] pyrimidin-7-yl]-phenyl}-N-methyl-acetamide
PT2387557E (pt) * 2009-01-13 2013-09-11 Interquim Sa Processo para a preparação de n-[5-(3-dimetilaminoacriloil)- 2-fluorofenil]-n-metil-acetamida
WO2013039985A2 (en) * 2011-09-12 2013-03-21 The Johns Hopkins University Serine protease inhibitors
CN102807569B (zh) * 2012-08-21 2015-02-25 四川大学 一种镇静催眠的化合物及其制备方法和用途
RU2672910C9 (ru) * 2013-02-21 2019-06-04 Калитор Сайенсез, ЛЛС Гетероароматические соединения как модуляторы фосфоинозитид-3-киназы

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE792533A (fr) * 1971-12-09 1973-06-08 Int Chem & Nuclear Corp Nouvelles pyrazolo (1,5a) pyrimidines et leur procede de preparation
US4626538A (en) * 1983-06-23 1986-12-02 American Cyanamid Company [7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidines
US4654347A (en) * 1983-06-23 1987-03-31 American Cyanamid Company Aryl and heteroaryl[[7-(3-disubstituted amino)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]methanones
NZ208554A (en) * 1983-06-23 1987-06-30 American Cyanamid Co (aryl and heteroaryl)-(7-(aryl and heteroaryl)-pyrazolo (1,5-a) pyrimidin-3-yl)-methanone derivatives and pharmaceutical compositions
SG30590G (en) * 1985-05-13 1995-09-18 American Cyanamid Co D7-(3-disubstituted amino) phenylaepyrazolod 1,5-aaepyrimidines
EP0264773A1 (en) * 1986-10-16 1988-04-27 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidines
DE4333705C2 (de) * 1993-10-02 2003-10-30 Guenter Ege Arylmethylsubstituierte Pyrazolo-azine, insbesondere 3-Arylmethylpyrazolo[1,5-a]pyrimidine und Verfahren zur Herstellung von 8-Arylmethyl-pyrazolo[5,1-c][1,2,4]triazinen
US5538977A (en) * 1995-03-17 1996-07-23 American Cyanamid Company 3-Substituted-7-[3-(imidazol-1-yl)phenyl]-pyrazolo[1,5-a]pyrimidines
BR0009539A (pt) * 1999-04-02 2006-06-06 Neurogen Corp composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
US6399621B1 (en) * 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto

Also Published As

Publication number Publication date
CN1829719A (zh) 2006-09-06
DK1648897T3 (da) 2009-04-06
US7947688B2 (en) 2011-05-24
NZ544349A (en) 2009-05-31
IL173252A0 (en) 2006-06-11
HRP20060009A2 (en) 2006-08-31
EP1648897A1 (en) 2006-04-26
TWI340140B (en) 2011-04-11
PT1648897E (pt) 2009-03-17
KR100840450B1 (ko) 2008-06-20
PE20050254A1 (es) 2005-04-11
US20060270690A1 (en) 2006-11-30
BRPI0412826A (pt) 2006-09-26
MA27944A1 (fr) 2006-06-01
UA81959C2 (en) 2008-02-25
CN100393721C (zh) 2008-06-11
DE602004018320D1 (de) 2009-01-22
EA200600316A1 (ru) 2006-06-30
MXPA06000754A (es) 2006-03-30
CA2532437C (en) 2010-01-26
CA2532437A1 (en) 2005-02-17
AR047017A1 (es) 2006-01-04
ES2245894B1 (es) 2006-12-01
UY28440A1 (es) 2004-11-08
WO2005014597A1 (en) 2005-02-17
EP1648897B1 (en) 2008-12-10
CL2004001814A1 (es) 2005-06-03
AU2004263278B2 (en) 2009-03-12
ES2222813A1 (es) 2005-02-01
PL1648897T3 (pl) 2009-07-31
HK1083844A1 (en) 2006-07-14
KR20060030908A (ko) 2006-04-11
JP2006528608A (ja) 2006-12-21
ES2222813B1 (es) 2005-12-16
ES2245894A1 (es) 2006-01-16
EA009519B1 (ru) 2008-02-28
ATE417048T1 (de) 2008-12-15
TW200510422A (en) 2005-03-16
PA8607501A1 (es) 2005-09-28
AU2004263278A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20082243L (no) Fremgangsmater og forbindelser for fremstiliing av CC-1065 analoger
NO20060580L (no) N-[3-(3-substituerte-pyrazolo[1,5 a]pyrimidin-7-yl)- fenyl]-sulfonamider samt preparater og metoder relatert dertil
NO20076479L (no) Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer
NO20062950L (no) 5,7-diaminopyrazolo `43-Dlpyrimidiner med PDE-5 inhiberende aktivitet
NO20076477L (no) Nye heterosykliske forbindelser som positive allosteriske modulatorer av metabotrope glutamatreseptorer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
NO20064456L (no) Thiadiazolidinoner som GSK-3 inhibitorer
NO20052802L (no) Pyrrolopyrimidinderivativer
NO331068B1 (no) Benzazepinderivater for behandling av nevrologiske forstyrrelser.
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
NO20076524L (no) Pyrazolforbindelse samt terapeutisk middel for diabetes som omfatter det samme
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
HU0302788D0 (en) New compounds
BR0213660A (pt) Composto, composição farmacêutica e método para tratar pacientes
NO20075749L (no) 1H-Quinazoline-2,4-diones and their use as ampa-receptor ligands
EA200601895A1 (ru) 3-(4-гетероарилциклогексиламино)циклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE493397T1 (de) Neuartige tetrazolderivate als positive allosterische modulatoren von metabotropen glutamatrezeptoren
NO20060195L (no) Kinolylamidderivater som CCR-5-antagonister
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
WO2006052889A3 (en) Quinolinone-carboxamide compounds
NO20082214L (no) 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer
ATE502945T1 (de) Ä ä5- ( phenyl) - 6- phenylpyrrolo ä2,1-füä2,1, 4ütriazin-4-ylüaminoü carbonsäurederivate und verwandte verbindungen als prostazyklin (pgi2) ip-rezeptor aktivatoren zur behandlung von kardiovaskulären erkrankungen
NO20060314L (no) Nicotinamid-derivater anvendbare som PDE4-inhibitorer
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
BR0114424A (pt) Derivados de 5-amidino-2-hidróxi benzeno sulfonamida, composições farmacêuticas contendo os mesmos e intermediários para a sua preparação

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application